Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies
March 27 2023 - 04:30PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in
serving science, and the University of California, San Francisco
(UCSF), will accelerate advanced cell therapies for difficult to
treat conditions, including cancer, rare diseases, and other
illnesses, from a newly opened cGMP manufacturing facility adjacent
to UCSF Medical Center’s Mission Bay campus.
The partnership between Thermo Fisher and UCSF, first announced
in 2021, has the potential to demonstrate that having scientists,
clinicians, and patients closer to a manufacturing site may
expedite the development of breakthrough treatments. UCSF’s initial
focus at the facility will be on treatments for glioblastoma,
multiple myeloma, and other cancers using updated approaches to
CAR-T and CRISPR technologies. Therapies for other difficult to
treat conditions will follow.
“Cell therapies represent a rapidly emerging field of
biotechnology with tremendous promise for future therapeutic
applications,” said Michel Lagarde, executive vice president and
chief operating officer of Thermo Fisher. “With a record number of
cell therapy approvals granted in the last two years, and CAR-T
therapies becoming earlier treatment options, we’re in a golden age
of biology, where new technologies and partnerships are evolving
and transforming clinical care.”
The San Francisco facility is part of Thermo Fisher’s global
pharma services network of more than 15 locations supporting cell
and gene therapies. In this facility, Thermo Fisher offers UCSF,
and other customers, process and analytical development
capabilities, as well as clinical and commercial manufacturing
services, for advanced therapies derived from either a patient’s
cells or from a donor source. Customers can also benefit from
Thermo Fisher’s drug development capabilities from discovery to
clinical research to commercialization.
“UCSF is one of the top clinical sites for CAR-T treatment, and
our scientists are leading the next-generation of CAR-T therapy
development,” said UCSF Chancellor Sam Hawgood, MBBS. “These
approaches will be tested soon in patients with solid tumors like
glioblastoma and later in other diseases, including
autoimmunity.”
Thermo Fisher is well positioned to provide integrated solutions
to cell therapy clients through high quality materials, services
and support that accelerate workflow from discovery to clinical
research and commercial manufacturing. To learn more about the
company’s capabilities, please visit thermofisher.com/patheon.
About UCSF
The University of California, San Francisco (UCSF) is
exclusively focused on the health sciences and is dedicated to
promoting health worldwide through advanced biomedical research,
graduate-level education in the life sciences and health
professions, and excellence in patient care. It includes UCSF
Health, which comprises three top-ranked hospitals, as well as
affiliations throughout the Bay Area. Learn more at
https://www.ucsf.edu, or see UCSF’s Fact Sheet.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue over $40 billion. Our Mission is to
enable our customers to make the world healthier, cleaner and
safer. Whether our customers are accelerating life sciences
research, solving complex analytical challenges, increasing
productivity in their laboratories, improving patient health
through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230327005006/en/
Media Contact Information: Sandy Pound Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
University of California, San Francisco Laura Kurtzman
415-317-3760 Laura.Kurtzman@ucsf.edu
Investor Contact Information: Rafael Tejada Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Aug 2023 to Sep 2023
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2022 to Sep 2023
